{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:34:26Z","timestamp":1794332066956,"version":"4.9.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"name":"Program of Shanghai Academic\/Technology Research Leader","award":["22XD1431400"],"award-info":[{"award-number":["22XD1431400"]}]},{"name":"Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant","award":["20172015"],"award-info":[{"award-number":["20172015"]}],"id":[{"id":"https:\/\/ror.org\/05tewj457","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Shanghai Hospital Development Center Clinical Science and Technology Innovation Project","award":["SHDC12024103"],"award-info":[{"award-number":["SHDC12024103"]}],"id":[{"id":"https:\/\/ror.org\/02zrtve16","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Key discipline project of the health commission of Jiading district","award":["XK202402"],"award-info":[{"award-number":["XK202402"]}]},{"name":"Medical Discipline Construction Program of Shanghai Pudong New Area Health Commission","award":["PWZzk2022-24"],"award-info":[{"award-number":["PWZzk2022-24"]}],"id":[{"id":"https:\/\/ror.org\/041s47w50","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hengrui Pharmaceuticals Co., Ltd"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"abstract":"\n Key Points<\/jats:title>\n \n \n \n This trial evaluated the effects of henagliflozin on cardiac structure and its safety in patients with heart failure with preserved ejection fraction on dialysis.<\/jats:p>\n <\/jats:list-item>\n \n \n At week 24, henagliflozin achieved a statistically significant reduction in left ventricular mass index versus placebo (\u22125.27 g\/m\n 2<\/jats:sup>\n ; 95% confidence interval, \u221210.02 to \u22120.53 g\/m\n 2<\/jats:sup>\n ).\n <\/jats:p>\n <\/jats:list-item>\n \n Henagliflozin was tolerable in the peritoneal dialysis and hemodialysis settings.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Few effective drug treatments exist for patients with heart failure with preserved ejection fraction (HFpEF) on dialysis. The aim of this study was to evaluate the effects of henagliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, on cardiac structure and its safety in such population.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n In this multicenter, randomized, double-blind, placebo-controlled trial, patients with HFpEF on dialysis were randomly assigned (1:1) to receive henagliflozin or placebo for 24 weeks. All enrolled participants received conventional therapy. The primary outcome was change in left ventricular mass index (LVMI) from baseline to week 24. The secondary outcomes were changes in the left atrial volume index, E\/e\u2019, e\u2019, and\n N<\/jats:italic>\n -terminal pro-brain natriuretic peptide and safety. Efficacy was assessed in the intention-to-treat population. Safety was assessed in the as-treated population. Analysis of covariance was used to assess treatment effects.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 112 participants were randomly assigned to the henagliflozin group (\n n<\/jats:italic>\n =56) and placebo group (\n n<\/jats:italic>\n =56). Of these, 60 participants were on hemodialysis and 52 were on peritoneal dialysis. From baseline to week 24, henagliflozin resulted in a greater reduction in least-squares mean (\u00b1SEM) change in LVMI than placebo (\u22123.27\u00b11.71 g\/m\n 2<\/jats:sup>\n versus 2.01\u00b11.69 g\/m\n 2<\/jats:sup>\n ), with a between-group difference of \u22125.27 g\/m\n 2<\/jats:sup>\n (95% confidence interval [CI], \u221210.02 to \u22120.53 g\/m\n 2<\/jats:sup>\n ;\n P<\/jats:italic>\n = 0.03). In the prespecified subgroup by dialysis modality, the between-group difference in LVMI change from baseline to week 24 was \u22126.86 g\/m\n 2<\/jats:sup>\n (95% CI, \u221214.02 to 0.29 g\/m\n 2<\/jats:sup>\n ) among participants on peritoneal dialysis and \u22123.91 g\/m\n 2<\/jats:sup>\n (95% CI, \u221210.45 to 2.63 g\/m\n 2<\/jats:sup>\n ) among participants on hemodialysis. No between-group differences in secondary outcomes were observed. The incidence of adverse events was similar between the henagliflozin and placebo groups (36% versus 34%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Henagliflozin was associated with a greater reduction in LVMI at week 24 compared with placebo and was tolerable in patients with HFpEF on dialysis. Larger studies are needed to confirm the LVMI-lowering effect of henagliflozin.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n ChiCTR2300073169.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.0000001201","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:00:27Z","timestamp":1788364827000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effects and Safety of Henagliflozin on Cardiac Structure in Patients with Heart Failure with Preserved Ejection Fraction on Dialysis"],"prefix":"10.2215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7312-8860","authenticated-orcid":false,"given":"Hao","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangshu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jiading District Central Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Punan Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8107-6792","authenticated-orcid":false,"given":"Shang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0744-6697","authenticated-orcid":false,"given":"Huihua","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2471-8119","authenticated-orcid":false,"given":"Zhiqing","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhua","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-8419","authenticated-orcid":false,"given":"Meng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9635-1291","authenticated-orcid":false,"given":"Wei","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-0132","authenticated-orcid":false,"given":"Leyi","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Molecular Cell Lab for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Department of Nephrology, Jiading District Central Hospital, Shanghai, China"},{"name":"Department of Nephrology, Punan Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the HELD-HF Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"6","key":"B1-20261008","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.ajkd.2012.12.030","article-title":"Heart failure with preserved or reduced ejection fraction in patients treated with peritoneal dialysis","volume":"61","author":"Wang","year":"2013","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"B2-20261008","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/ehf2.14447","article-title":"Heart failure with preserved ejection fraction in haemodialysis patients: prevalence, diagnosis, risk factors, prognosis","volume":"10","author":"Yu","year":"2023","journal-title":"ESC Heart Fail."},{"issue":"9224","key":"B3-20261008","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(00)02456-9","article-title":"Premature cardiovascular disease in chronic renal failure","volume":"356","author":"Baigent","year":"2000","journal-title":"Lancet."},{"issue":"12","key":"B4-20261008","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ckj\/sfac146","article-title":"Left ventricular dysfunction with preserved ejection fraction: the Most common left ventricular disorder in chronic kidney disease patients","volume":"15","author":"Mark","year":"2022","journal-title":"Clin Kidney J."},{"issue":"22","key":"B5-20261008","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"15","key":"B6-20261008","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"2","key":"B7-20261008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"issue":"37","key":"B8-20261008","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J."},{"issue":"18","key":"B9-20261008","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/American heart association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation."},{"issue":"37","key":"B10-20261008","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur Heart J."},{"issue":"1","key":"B11-20261008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12933-024-02424-7","article-title":"Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol."},{"issue":"supplment_1","key":"B12-20261008","doi-asserted-by":"crossref","first-page":"gfad063a_3382","DOI":"10.1093\/ndt\/gfad063a_3382","article-title":"#3382 reasons for dialysis initiation and safety of dapagliflozin among dialysis participants: new insights from DAPA-CKD","volume":"38","author":"Heerspink","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"11","key":"B13-20261008","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40262-023-01300-z","article-title":"Pharmacokinetics of henagliflozin in dialysis patients with diabetes","volume":"62","author":"Ding","year":"2023","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"B14-20261008","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10554-021-02443-5","article-title":"Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial","volume":"38","author":"Ersb\u00f8ll","year":"2022","journal-title":"Int J Cardiovasc Imaging."},{"issue":"11","key":"B15-20261008","doi-asserted-by":"crossref","first-page":"EVIDoa2500158","DOI":"10.1056\/EVIDoa2500158","article-title":"Cardiac effects of dapagliflozin in people with chronic kidney disease","volume":"4","author":"Bartholdy","year":"2025","journal-title":"NEJM Evid."},{"issue":"8","key":"B16-20261008","doi-asserted-by":"crossref","first-page":"e087617","DOI":"10.1136\/bmjopen-2024-087617","article-title":"Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial","volume":"14","author":"Yan","year":"2024","journal-title":"BMJ Open."},{"issue":"6","key":"B17-20261008","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/ndt\/gfp067","article-title":"Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients","volume":"24","author":"Wang","year":"2009","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"B18-20261008","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.amjcard.2005.11.090","article-title":"N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients","volume":"97","author":"Khan","year":"2006","journal-title":"Am J Cardiol."},{"issue":"3","key":"B19-20261008","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.echo.2017.11.013","article-title":"Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update","volume":"31","author":"Porter","year":"2018","journal-title":"J Am Soc Echocardiogr."},{"issue":"12","key":"B20-20261008","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1681\/ASN.V12122759","article-title":"Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study","volume":"12","author":"London","year":"2001","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B21-20261008","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12882-022-02831-6","article-title":"Prognostic values of left ventricular mass index progression in incident peritoneal dialysis patients: a prospective cohort study","volume":"23","author":"Chen","year":"2022","journal-title":"BMC Nephrol."},{"issue":"4","key":"B22-20261008","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1523-1755.2004.00530.x","article-title":"Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression","volume":"65","author":"Zoccali","year":"2004","journal-title":"Kidney Int."},{"issue":"4","key":"B23-20261008","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int."},{"issue":"5","key":"B24-20261008","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/joim.13770","article-title":"Roxadustat reduces left ventricular mass index compared to rHuEPO in haemodialysis patients in a randomized controlled trial","volume":"295","author":"Tan","year":"2024","journal-title":"J Intern Med."},{"issue":"16","key":"B25-20261008","doi-asserted-by":"crossref","first-page":"e015103","DOI":"10.1161\/JAHA.119.015103","article-title":"Effect of Luseogliflozin on heart failure with preserved ejection fraction in patients with diabetes mellitus","volume":"9","author":"Ejiri","year":"2020","journal-title":"J Am Heart Assoc."},{"issue":"4","key":"B26-20261008","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/ggi.14363","article-title":"Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: the EXCEED randomized controlled multicenter study","volume":"22","author":"Akasaka","year":"2022","journal-title":"Geriatr Gerontol Int."},{"issue":"22","key":"B27-20261008","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation."},{"issue":"1","key":"B28-20261008","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","article-title":"Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies","volume":"22","author":"Carluccio","year":"2023","journal-title":"Cardiovasc Diabetol."},{"issue":"2","key":"B29-20261008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/1744-9987.12756","article-title":"Diastolic dysfunction, an underestimated new challenge in dialysis","volume":"23","author":"Escoli","year":"2019","journal-title":"Ther Apher Dial."},{"issue":"1","key":"B30-20261008","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12882-025-04324-8","article-title":"A change of heart: the effect of high flow arteriovenous fistulas on cardiovascular outcomes - a systematic review and synthesis without meta-analysis (SWiM)","volume":"26","author":"Shah","year":"2025","journal-title":"BMC Nephrol."},{"issue":"7321","key":"B31-20261008","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/bmj.323.7321.1123","article-title":"Statistics notes: analysing controlled trials with baseline and follow up measurements","volume":"323","author":"Vickers","year":"2001","journal-title":"BMJ."},{"issue":"1","key":"B32-20261008","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cardfail.2022.09.013","article-title":"Managing heart failure in patients on dialysis: State-of-the-Art review","volume":"29","author":"Khan","year":"2023","journal-title":"J Card Fail."},{"issue":"11","key":"B33-20261008","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2215\/CJN.0000000000000221","article-title":"Will SGLT2 inhibitors be effective and safe in patients with severe CKD, dialysis, or kidney transplantation","volume":"18","author":"Heerspink","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"B34-20261008","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.0000000000000196","article-title":"Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients","volume":"18","author":"Barreto","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B35-20261008","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.12182","article-title":"Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment","volume":"16","author":"Macha","year":"2014","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"B36-20261008","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1681\/ASN.0000000724","article-title":"Volume assessment in patients undergoing long-term dialysis","volume":"36","author":"Lazarus","year":"2025","journal-title":"J Am Soc Nephrol."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:00:31Z","timestamp":1791471631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":36,"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001201","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2026-03-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}